Targeting survivin in cancer: patent review

Bibliography

• Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin Ther Targets 2008;12(4):463-76
   Google Scholar
• Kanwar RK, Cheung CHA, Chang JY, Recent advances in anti-survivin treatments for cancer. Curr Med Chem 2010;17(15):1509-15
   Google Scholar
• Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 2009;35(7):553-62
   Google Scholar
• Mantovani A, Garlanda C, Allavena P. Molecular pathways and targets in cancer-related inflammation. Ann Med 2010;42(3):161-70
   Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140(6):883-99
   Google Scholar
• Cheung CHA, Chen H-H, Cheng L-T, Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells. Mol Cancer 2010;9(1):77
   Google Scholar
• Altieri DC. Survivin and IAP proteins in cell-death mechanisms. Biochem J 2010;430(2):199-205
   Google Scholar
• Chan KS, Wong CH, Huang YF, Survivin withdrawal by nuclear export failure as a physiological switch to commit cells to apoptosis. Cell Death Dis 2010;1:e57
   Google Scholar
• Altieri DC. New wirings in the survivin networks. Oncogene 2008;27(48):6276-84
   Google Scholar
• Hayes I, Cotter T, Seery L, Survivin. US20060160095; 2006
   Google Scholar
• Hentsch B, Ducker K, Hock B. Human survivin interacting protein 1 (SIP-1). US7166701; 2007
   Google Scholar
• Baratchi S, Kanwar RK, Cheung CH, Kanwar JR. Proliferative and protective effects of SurR9-C84A on differentiated neural cells. J Neuroimmunol 2010;227(1-2):120-32
   Google Scholar
• Sendtner M, Rapp UR, Wiese S. Method and test system for identifying substances which protect nerve cells. US20040082014; 2004
   Google Scholar
• Altieri DC. Survivin, a protein that inhibits cellular apoptosis and its modulation. US6943150; 2005
   Google Scholar
• Conway E. Use of survivin to treat kidney failure. US20090149373; 2009
   Google Scholar
• Hentsch B, Hock B. Novel survivin interacting protein TPR1. US20060127937; 2006
   Google Scholar
• Dumas M, Bonte F, Renimel I. Method of anti-ageing cosmetic care by stimulation of survivin expression. US20100040706; 2010
   Google Scholar
• Li F. Compositions and methods for identifying agents that alter expression of survivin. US7569221; 2009
   Google Scholar
• Cai X, Qian C, Gould S, Multi-functional small molecules as anti-proliferative agents. US20080221132; 2008
   Google Scholar
• Hayes I, Cotter T, Seery L, A role for survivin in apoptosis of myeloid cells. WO2003091384; 2003
   Google Scholar
• Altieri DC. Methods for selectively modulating survivin apoptosis pathways. US7553821; 2009
   Google Scholar
• Altieri DC, Sessa WC. Survivin promotion of angiogenesis. WO2001046455; 2001
   Google Scholar
• Yang L. Methods and applications of molecular beacon imaging for cancer cell detection. WO2006060561; 2006
   Google Scholar
• Conn MM, Pelligrini M, Hwang S, Methods for identifying small molecules that bind specific rna structural motifs. US20050142545; 2005
   Google Scholar
• Caldas H, Altura RA. Targeted expression of apoptosis-inducing genes for disease treatment. WO2006026451; 2006
   Google Scholar
• Waxman DJ, Schwartz PS. Method of using anti-apoptotic factors in gene expression. US20060057109; 2006
   Google Scholar
• Lokshin A. Enhanced diagnostic multimarker serological profiling. US20070042405; 2007
   Google Scholar
• Yu Q. Compositions of angiopoietin, fragments, mutants and analogs thereof and uses of the same. US7569543; 2009
   Google Scholar
• Wang L, Bulawa C. Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins. US20080131907; 2008
   Google Scholar
• Zhang SH, Gregory PD. Anti-angiogenic methods and compositions. US20080187523; 2008
   Google Scholar
• Li CJ, Rogoff H, Chen C-R. Methods and compositions for modulating CHK2 pathways and methods for screening for same. US20060204993; 2006
   Google Scholar
• Heyer J, O'hagan RC. Tumor-specific expression of reporter genes. US20070275376; 2007
   Google Scholar
• Kanwar JR, Shen WP, Kanwar RK, Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 2001;93(20):1541-52
   Google Scholar
• Kwon ED, Cheville JC, Krambeck A, B7-H1 and survivin in cancer. US20100015642; 2010
   Google Scholar
• Reed JC, Krajewski S. Methods for determining the prognosis for patients with a prostate neoplastic condition using inhibitor of apoptosis polypeptides. US7704700; 2010
   Google Scholar
• Herweijer H, Wolff JA, Bates MK, Methods for genetic immunization. US20070021364; 2007
   Google Scholar
• Baratchi S, Kanwar RK, Kanwar JR. Survivin: a target from brain cancer to neurodegenerative disease. Crit Rev Biochem Mol Biol 2010; doi: 10.3109/10409238.2010.516740
   Google Scholar
• Altieri DC. Method for selectively modulating the interactions between survivin and tubulin. US6346389; 2002
   Google Scholar
• Markham AF, Guillou PJ. Combined cancer marker. WO2000001847; 2000
   Google Scholar
• Li F, Ghadersohi A, Apontes P. Methods for analysis of PDEF and survivin as interconnected cancer biomarkers and targets for personalized medicine. US 20090081674; 2009
   Google Scholar
• Witta S, Yoshida K, Dziadziuszko R, Markers for assessing the susceptibility of cancer to IGF-1R treatment. WO2010022268; 2010
   Google Scholar
• Murphy M. Compositions and methods for p53-mediated repression of gene expression. US20030083482; 2003
   Google Scholar
• Lokshin AE, Gorelik E. Multifactorial assay for cancer detection. US20050069963; 2005
   Google Scholar
• Rammensee H-G, Stevanovic S, Gouttefanges C, Novel and powerful MHC-class II peptides derived from survivin. US20100029571; 2010
   Google Scholar
• Salah-eddine L-C, Zhengbin Y, Sanjaya S. Antagonist OX40 antibodies and their use in the treatment of inflammatory and autoimmune diseases. US20100136030; 2010
   Google Scholar
• Wang X, Munier G, Moratille S, Cd4+ survivin epitopes and uses thereof. US20090004214; 2009
   Google Scholar
• He B, You L, Xu Z, Methods for treating cancer by inhibiting WNT signaling. WO2004032838; 2004
   Google Scholar
• Taylor DD, Gercel-taylor C. Methods of detecting autoantibodies for diagnosis and characterizing disorders. US20100055724; 2010
   Google Scholar
• Lee FD, Meng X, Afeyan NB, Small molecule and peptide arrays and uses thereof. US20050255491; 2005
   Google Scholar
• Waelti ER. Novel strategies for protein vaccines. US20060275777; 2006
   Google Scholar
• Straten EPT, Andersen MH. Survivin-derived peptides and use thereof. US20040210035; 2004
   Google Scholar
• Nichols SW, Chan RCK, Jouben-steele L. Method of detecting neoplastic,hyperplastic,cytologically dysplastic and/or premalignant cellular growth or proliferation. WO2001053535; 2001
   Google Scholar
• Singh H, Emmerich N, Walter S, Tumour-associated peptides binding to human leukocyte antigen (HLA) class I OR II molecules and related anti-cancer vaccine. US20090274714; 2009
   Google Scholar
• Zhou T, Kimberly RP. Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists. US20100135951; 2010
   Google Scholar
• Hoerr I, Pascolo S. Combination therapy for immunostimulation. US20080025944; 2008
   Google Scholar
• Khvorova A, Reynolds A, Leake D, siRNA targeting survivin. US7608707; 2009
   Google Scholar
• Patel BK. Composition comprising a survivin oligonucleotide and gemcitabine for the treatment of cancer. US20070244065; 2007
   Google Scholar
• Quay SC, Mcswiggen J, Vaish NK, Nucleic acid compounds for inhibiting gene expression and uses thereof. US20100105134; 2010
   Google Scholar
• Dobie KW, Dean NM, Bennett FC. Compositions and their uses directed to HBXIP. US20100056607; 2010
   Google Scholar
• Ahmed R, Amara R, Freeman G, Compositions and methods for the treatment of infections and tumors. US20100040614; 2010
   Google Scholar
• Yu HE, Jove R, Cheng JQ, Combination therapies for cancer and proliferative angiopathies. US20060030536; 2006
   Google Scholar
• Xu J, Qin X. Method of detecting the expression of PPN/MG61 and the use of it. US7667014; 2010
   Google Scholar
• Bhat B, Patel BK, Swayze E. Modulation of survivin expression. US7541344; 2009
   Google Scholar
• Krissansen GW, Sun X, Kanwar JR. Tumor treating combinations, compositions and methods. US20050261220; 2005
   Google Scholar
• Altura R, Caldas H, Holloway M. Survivin-directed RNA interference-compositions and methods. US20060276423; 2006
   Google Scholar
• Manoharan M, Rajeev KG. Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine. US7674778; 2010
   Google Scholar
• Hansen B, Thrue CA, Westergaard M, Oligomeric compounds for the modulation of survivin expression. US7713738; 2010
   Google Scholar
• Manoharan M, Rajeev KG, Jayaraman M, Folate conjugates. US20090247614; 2009
   Google Scholar
• Brown BD. Dosing and scheduling of oligomers. US20070270371; 2007
   Google Scholar
• Li CJ, Sun X, Rogoff H, Compositions of asymmetric interfering RNA and uses thereof. US20090208564; 2009
   Google Scholar
• Rosenbohm C, Kjaerulff LS, Westergaard M, LNA oligonucleotides and the treatment of cancer. US20090181914; 2009
   Google Scholar
• Tu SP, Lin MC-M, Kung H-F, Adeno-associated virus-mediated survivin mutants and methods related thereto. US20070081978; 2007
   Google Scholar
• Mathis JM, Debenedetti A, Curiel DT. Conditionally replicating viruses and methods for cancer virotherapy. US20060275262; 2006
   Google Scholar
• Kazhdan I. Methods and compositions for combinatorial approaches to cancer gene therapy. US20080108582; 2008
   Google Scholar
• Hui KM, Al-wei IH, Lam PYP. Compositions and methods for treating disease. WO2005085455; 2005
   Google Scholar
• Andersen MH. Survivin peptide vaccine. EP1853305; 2007
   Google Scholar
• Leason H, Spitler LE. Survivin and peptides thereof, as an anti-cancer vaccine. WO2000003693; 2000
   Google Scholar
• Costa RH, Costa JB, Wang I-C. Method for inhibiting angiogenesis. US20100056441; 2010
   Google Scholar
• Graddis T, Laus R, Diegel M, Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease. US7597894; 2009
   Google Scholar
• Crisanti A. Peptides for use as translocation factors. US20040234527; 2003
   Google Scholar
• Butz K, Crnkovic-mertens I, Hoppe-seyler F, Peptides for inducing apoptosis in tumor cells. WO2004003008; 2004
   Google Scholar
• Mascarenhas D. Metal-binding therapeutic peptides. WO2008115525; 2008
   Google Scholar
• Cheung CHA, Kanwar J, Krissansen GW. A cell-permeable dominant-negative survivin protein as a tool to understand how survivin maintains tumour cell survival. Ejc Suppl 2006;4(12):149-49
   Google Scholar
• Sugita T, Yoshikawa T, Mukai Y, Improved cytosolic translocation and tumor-killing activity of Tat-shepherdin conjugates mediated by co-treatment with Tat-fused endosome-disruptive HA2 peptide. Biochem Biophys Res Commun 2007;363(4):1027-32
   Google Scholar
• Meli M, Pennati M, Curto M, Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead. J Med Chem 2006;49(26):7721-30
   Google Scholar
• Gyurkocza B, Plescia J, Raskett CM, Antileukemic activity of shepherdin and molecular diversity of Hsp90 inhibitors. J Natl Cancer Inst 2006;98(15):1068-77
   Google Scholar
• Patel BK. Method of treating a cancer with a survivin antisense oligonucleotide and paclitaxel. US20090247611; 2009
   Google Scholar
• Gera L, Stewart JM, Chung LWK, Compositions and methods for treating bone cancer. US20100144678; 2010
   Google Scholar
• Jove R, Minton SE, Muro-cacho CA, Methods of predicting responsiveness to chemotherapeutic agents and selecting treatments. US20070031871; 2007
   Google Scholar
• Byth K, Palakurthi S, Yu L, Methods for cancer treatment using TAK1 inhibitors. US20090312396; 2009
   Google Scholar
• Altieri DC, O'connor DS. Enhancement of taxane-based chemotherapy by a CDK1 antagonist. US6949558; 2005
   Google Scholar
• Nemeth J. Method of using IL6 antagonists with mitoxantrone for prostate cancer. US20080081041; 2008
   Google Scholar
• Mohapatra S, Pledger JW. XIAP-targeted prostate cancer therapy. US20070027169; 2007
   Google Scholar
• Huang RCC, Heller JD, Chang C-C. Method for treatment of tumors using nordihydroguaiaretic acid derivatives. US20040127562; 2004
   Google Scholar
• Nakshatri H, Sweeney CJ. Use of parthenolide to inhibit cancer. US6890946; 2005
   Google Scholar
• Aggarwal BB, Shishodia S. Guggulsterone: an inhibitor of nuclear factor – kappaB and IkappaBalpha kinase activation and uses thereof. US20060019907; 2006
   Google Scholar
• Kahn M, Eguchi M, Moon SH, Compounds useful for treatment of cancer, compositions containing the same, and methods of their use. US6762185; 2004
   Google Scholar
• Moon SH, Chung JU, Lee SC, Reverse-turn mimetics and method relating thereto. US20040072831; 2004
   Google Scholar
• Hergenrother PJ, Nesterenko V, Putt K, Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells. US7632972; 2009
   Google Scholar
• Bhalla KN. Histone deacetylase inhibitor enhancement of trail-induced apoptosis. US20070207119; 2007
   Google Scholar
• Turkson J, Jove R, Sebti SM. Platinum IV complex inhibitor. US20070123502; 2007
   Google Scholar
• Tolcher AW, Mita A, Lewis LD, Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 2008;26(32):5198-203
   Google Scholar
• Nakahara T, Takeuchi M, Kinoyama I, YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007;67(17):8014-21
   Google Scholar
• Iwasa T, Okamoto I, Takezawa K, Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br J Cancer 2010;103(1):36-42
   Google Scholar
• Iwasa T, Okamoto I, Suzuki M, Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res 2008;14(20):6496-504
   Google Scholar
• Kanwar JR, Mahidhara G, Kanwar RK. Recent advances in nanoneurology for drug delivery to the brain. Curr Nanosci 2009;5(4):441-48
   Google Scholar
• Baratchi S, Kanwar RK, Khoshmanesh K, Promises of nanotechnology for drug delivery to brain in neurodegenerative diseases. Current Nanosci 2009;5(1):15-25
   Google Scholar
• He B, You L, Xu Z, Methods for treating cancer by inhibiting WNT signaling. US20090304695; 2009
   Google Scholar
• Nakahara T, Yamanaka K, Kita A, Method of treating cancer by co-administration of anticancer agents. US20080166344; 2008
   Google Scholar